ArticleMedicine2026
Burden of CNS neoplasms in the Middle East and North Africa from 1990 to 2023, with projections to 2050: Insights from Global Burden of Disease.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) neoplasms are uncommon but highly consequential malignancies that account for substantial neurological disability and premature mortality. The Middle East and North Africa (MENA) region is marked by rapid population growth, aging, and uneven health system capacity, yet comprehensive long-term evaluations of CNS neoplasm burden across countries, sexes, and age groups remain limited. We analyzed data from the Global Burden of Disease 2023 study to assess trends in incidence, prevalence, and mortality from CNS neoplasms in the MENA region from 1990 to 2023, with projections to 2050. Age-standardized incidence, prevalence, and mortality rates per 1,00,000 population were estimated. Temporal trends were evaluated using Joinpoint regression to calculate annual percent change and average annual percent change (AAPC) with 95% confidence intervals. Analyses were stratified by sex, age group, and country. Between 1990 and 2023, the age-standardized mortality rate remained largely stable with a small but significant upward trend (AAPC 0.09%). Mortality rates were consistently higher among males. Adults aged 20 years and older experienced rising age-standardized mortality (AAPC 0.58%), whereas mortality declined among individuals younger than 20 years (AAPC-0.90%). Incidence increased in both absolute numbers and age-standardized rates (AAPC 0.42%). Prevalence also rose steadily, with the age-standardized prevalence rate increasing from 13.46 to 19.51 per 1,00,000 (AAPC 1.13%), driven mainly by adults. The burden of CNS neoplasms in the MENA region has intensified over the past 3 decades, highlighting the need for improved surveillance, earlier diagnosis, and expanded access to specialized neuro-oncological care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.